News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmuneRegen BioSciences, Inc. (IRBO) Signs Lovelace Respiratory Research Institute as Development and Regulatory Partner



2/19/2008 9:13:09 AM

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--ImmuneRegen BioSciences, a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTCBB: IRBO), today announced it has finalized an agreement with Lovelace Respiratory Research Institute (LRRI) in Albuquerque, N.M., to provide a broad range of product development services pertaining to inhalation and intranasal drug delivery, and associated regulatory affairs support. This strategic relationship is expected to support ImmuneRegen’s preparation for an Investigational New Drug Application (IND) for Homspera™.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES